Streptokinase Disease Interactions
There is 1 disease interaction with streptokinase.
Thrombolytic agents (applies to streptokinase) bleeding risks
Major Potential Hazard, High plausibility. Applicable conditions: Gastrointestinal Hemorrhage, Retinal Hemorrhage, Cerebral Vascular Disorder, Hypertension, Infectious Endocarditis
The use of thrombolytics is contraindicated in patients with an active bleed (internal), trauma/surgery (recent CPR/intracranial/intraspinal surgery within 2 months), bleeding diathesis, history of cerebrovascular (CV) accident, intracranial defect (aneurysm, arteriovenous malformation, neoplasm), or severe uncontrolled arterial hypertension (SBP>180/DBP>110). Risk versus benefit should be carefully considered in the following conditions and thrombolytic therapy administered with caution in patients with recent (10 days) serious GI bleed or recent (10 days) surgical procedure (coronary bypass graft, obstetrical delivery, organ biopsy, puncture of noncompressible vessel), left heart thrombus, subacute bacterial endocarditis, hemostatic defect, CV disease, diabetic hemorrhagic retinopathy, or pregnancy. Clinical monitoring of hematopoietic, bleeding and coagulation functions is recommended prior to initiation of thrombolytic therapy. Measures of fibrinolytic activity and/or coagulation functions during infusion do not correlate with efficacy or risk of bleeding.
References (29)
- Kase CS, Pessin MS, Zivin JA, del Zoppo GJ, Furlan AJ, Buckley JW, Snipes RG, LittleJohn JK (1992) "Intracranial hemorrhage after coronary thrombolysis with tissue plasminogen activator." Am J Med, 92, p. 384-90
- Califf RM, Topol EJ, George BS, Boswick JM, Abbottsmith C, Sigmon KN, Candela R, Masek R, Kereiakes D, O'Neill WW, et al. (1988) "Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction." Am J Med, 85, p. 353-9
- Topol EJ, Herskowitz A, Hutchins GM (1986) "Massive hemorrhagic myocardial infarction after coronary thrombolysis." Am J Med, 81, p. 339-43
- Dabbs CK, Aaberg TM, Aguilar HE, Sternberg P, Jr Meredith TA, Ward AR (1990) "Complications of tissue plasminogen activator therapy after vitrectomy for diabetes." Am J Ophthalmol, 110, p. 354-60
- Fromm RE, Hoskins E, Cronin L, Pratt CM, Spencer WH, Roberts R (1991) "Bleeding complications following initiation of thrombolytic therapy for acute myocardial infarction: a comparison of helicopter- transported and nontransported patients." Ann Emerg Med, 20, p. 892-5
- Kase CS, O'Neal AM, Fisher M, Girgis GN, Ordia JI (1990) "Intracranial hemorrhage after use of tissue plasminogen activator for coronary thrombolysis." Ann Intern Med, 112, p. 17-21
- Maggioni AP, Franzosi MG, Santoro E, White H, Van de Werf F, Tognoni G (1992) "The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico II (GISSI-2), andThe International Study Group." N Engl J Med, 327, p. 1-6
- Garcia-Rubira JC, Lopez V, Rojas J, Garcia-Martinez JT, Cruz JM (1991) "Thrombolytic therapy soon after left heart catheterization--is it safe?" Intensive Care Med, 17, p. 501-3
- Tisdale JE, Colucci RD, Ujhelyi MR, Kluger J, Fieldman A, Chow MS (1992) "Evaluation and comparison of the adverse effects of streptokinase and alteplase." Pharmacotherapy, 12, p. 440-4
- Brenot F, Pacouret G, Meyer G, Sors H, Charbonnier B, Simonneau G (1991) "Adverse reactions with anistreplase." Lancet, 338, p. 114-5
- McNeill AJ, Roberts MJ, Wilson CM, Dalzell GW, Dickey W, Flannery DJ, Campbell NP, Khan MM, Molajo AO, Patterson GC, et al. (1991) "Anistreplase in early acute myocardial infarction and the one-year follow-up." Int J Cardiol, 31, p. 39-49
- Hirsch DR, Goldhaber SZ (1990) "Bleeding time and other laboratory tests to monitor the safety and efficacy of thrombolytic therapy." Chest, 97, s124-31
- Levine SR, Brott TG (1992) "Thrombolytic therapy in cerebrovascular disorders." Prog Cardiovasc Dis, 34, p. 235-62
- Hanaway J, Torack R, Fletcher AP, Landau WM (1976) "Intracranial bleeding associated with urokinase therapy for acute ischemic hemispheral stroke." Stroke, 7, p. 143-6
- Erlemeier HH, Zangemeister W, Burmester L, Schofer J, Mathey DG, Bleifeld W (1989) "Bleeding after thrombolysis in acute myocardial infarction." Eur Heart J, 10, p. 16-23
- Schneeman NJ, Stein EM (1991) "Thrombolytic therapy and gastrointestinal bleeding." Am Fam Physician, 43, 53-6,
- Haugeberg G, Bonarjee V, Dickstein K (1989) "Fatal intrathoracic haemorrhage after cardiopulmonary resuscitation and treatment with streptokinase and heparin." Br Heart J, 62, p. 157-8
- Berridge DC, Makin GS, Hopkinson BR (1989) "Local low dose intra-arterial thrombolytic therapy: the risk of stroke or major haemorrhage." Br J Surg, 76, p. 1230-3
- De Jaegere PP, Arnold AA, Balk AH, Simoons ML (1992) "Intracranial hemorrhage in association with thrombolytic therapy: incidence and clinical predictive factors." J Am Coll Cardiol, 19, p. 289-94
- Aldrich MS, Sherman SA, Greenberg HS (1985) "Cerebrovascular complications of streptokinase infusion." JAMA, 253, p. 1777-9
- London NJ, Williams B, Stein A (1993) "Systemic thrombolysis causing haemorrhage around a prosthetic abdominal aortic graft." BMJ, 306, p. 1530-1
- McLeod DC, Coln WG, Thayer CF, Perfetto EM, Hartzema AG (1993) "Pharmacoepidemiology of bleeding events after use of r-alteplase or streptokinase in acute myocardial infarction." Ann Pharmacother, 27, p. 956-62
- (2001) "Product Information. Eminase (anistreplase)." SmithKline Beecham
- (2022) "Product Information. Abbokinase Open-Cath (urokinase)." Abbott Pharmaceutical
- (2001) "Product Information. Activase (alteplase)." Genentech
- (2001) "Product Information. Streptase (streptokinase)." Astra-Zeneca Pharmaceuticals
- Wagstaff AJ, Gillis JC, Goa KL (1995) "Alteplase - a reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction." Drugs, 50, p. 289-316
- Levine MN, Goldhaber SZ, Gore JM, Hirsh J Califf RM (1995) "Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism." Chest, 108 Suppl, s291-301
- (2001) "Product Information. Retavase (reteplase)." Boehringer Mannheim
Switch to consumer interaction data
Streptokinase drug interactions
There are 154 drug interactions with streptokinase.
Streptokinase alcohol/food interactions
There is 1 alcohol/food interaction with streptokinase.
Report options
More about streptokinase
- streptokinase consumer information
- Check interactions
- Compare alternatives
- Reviews (2)
- Side effects
- Dosage information
- During pregnancy
- Drug class: thrombolytics
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Eliquis
Eliquis (apixaban) is used to reduce the risk of stroke and systemic embolism in patients with ...
Valsartan
Valsartan is an angiotensin II receptor blocker (ARB) that may be used to treat high blood pressure ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Warfarin
Warfarin is an anticoagulant used to prevent heart attacks, strokes, and blood clots. Learn about ...
Apixaban
Apixaban systemic is used for deep vein thrombosis, deep vein thrombosis prophylaxis after hip ...
Atenolol
Atenolol is used to treat angina (chest pain) and hypertension (high blood pressure). Learn about ...
Propranolol
Propranolol is a beta-blocker that is used to treat tremors, chest pain, high blood pressure, heart ...
Clopidogrel
Clopidogrel systemic is used for acute coronary syndrome, acute coronary syndrome, prophylaxis ...
Aspirin
Aspirin is used to treat mild to moderate pain and to reduce fever or inflammation. Learn about ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.